Zepbound (Tirzepatide for Weight + OSA)

Zepbound is Eli Lilly's brand name for tirzepatide for chronic weight management (FDA-approved November 2023) and for moderate-to-severe obstructive sleep apnea in adults with obesity (FDA-approved December 2024 — the first drug ever FDA-approved for OSA).

At a glance

• Generic name: tirzepatide
• FDA-approved indications: Chronic weight management (Nov 2023); moderate-to-severe OSA in adults with obesity (Dec 2024)
• Manufacturer: Eli Lilly
• List price (cash, no coverage): ~$1,059/month
• Cash-pay program: Lilly Direct vial program from ~$349/month for lower doses

The OSA indication

In December 2024, FDA approved Zepbound for moderate-to-severe OSA in adults with obesity. The basis was SURMOUNT-OSA (NEJM 2024), which showed AHI reduction of ~30 events/hour at 52 weeks. Zepbound is the first drug ever FDA-approved for OSA. See our sleep apnea page.

Dosing

• Start: 2.5 mg weekly × 4 weeks.
• Titration: 5 → 7.5 → 10 → 12.5 → 15 mg.
• Maintenance: 5, 10, or 15 mg weekly (depending on response).

Cost

List ~$1,059/month. Lilly Direct vial program: lower-cost cash-pay starting around $349/month for 2.5 mg/5 mg vials. With insurance for weight indication: highly variable; OSA indication coverage increasing. Compounded tirzepatide cash-pay is substantially lower ($186–$269/mo).

See also

· All about tirzepatide · Mounjaro vs Zepbound · OSA indication detail